Skip to collection list Skip to video grid
Skip to collection list Skip to video grid

Infectious Diseases

Effectiveness of Nirsevimab against RSV and RSV-Related Events in Infants

This US study estimated the effectiveness of nirsevimab against respiratory syncytial virus with lower respiratory tract disease in healthy term infants during the 2023-2024 season.

Click here to read the article
Read More
Read Less

categories

View more in
Infectious Diseases

Currently loaded videos are 1 through 15 of 104 total videos.

First page loaded, no previous page available
Load Next Page
3:50
Postnatal Antiretroviral Prophylaxis and Perinatal HIV Infection in Medicaid-Enrolled Infants
Postnatal Antiretroviral Prophylaxis and Perinatal HIV Infection in Medicaid-Enrolled Infants
4:02
Disparities in Nirsevimab Uptake Across a Pediatric Primary Care Network
Disparities in Nirsevimab Uptake Across a Pediatric Primary Care Network
4:00
Youth Hospitalized for Suicidality: Caregiver Perspectives on Firearm Safety Guidance
Youth Hospitalized for Suicidality: Caregiver Perspectives on Firearm Safety Guidance
3:59
Effectiveness of Nirsevimab against RSV and RSV-Related Events in Infants
Effectiveness of Nirsevimab against RSV and RSV-Related Events in Infants
4:13
Risk of Bacterial Infections in Febrile Infants 61 to 90 Days Old with Respiratory Viruses
Risk of Bacterial Infections in Febrile Infants 61 to 90 Days Old with Respiratory Viruses
4:10
Recommendations for Pneumonia in Hospitalized Children with Neurologic Impairment
Recommendations for Pneumonia in Hospitalized Children with Neurologic Impairment
3:38
Late-Onset Sepsis Among Extremely Preterm Infants During the COVID-19 Pandemic
Late-Onset Sepsis Among Extremely Preterm Infants During the COVID-19 Pandemic
4:13
Optimizing Management of Febrile Young Infants Without Serum Procalcitonin
Optimizing Management of Febrile Young Infants Without Serum Procalcitonin
3:54
Early and Long-Term Adverse Outcomes of In-Utero Zika Exposure
Early and Long-Term Adverse Outcomes of In-Utero Zika Exposure
4:09
Invalid Vaccine Doses Among Children Ages 0-35 months: 2011-2020
Invalid Vaccine Doses Among Children Ages 0-35 months: 2011-2020
4:06
Risk of Transmission of Vaccine-Strain Rotavirus in a NICU that Routinely Vaccinates
Risk of Transmission of Vaccine-Strain Rotavirus in a NICU that Routinely Vaccinates
4:15
Accuracy of Screening Tests for the Diagnosis of Urinary Tract Infection in Young Children
Accuracy of Screening Tests for the Diagnosis of Urinary Tract Infection in Young Children
4:07
RSV Neutralizing Antibodies Following Nirsevimab and Palivizumab Dosing
RSV Neutralizing Antibodies Following Nirsevimab and Palivizumab Dosing
4:12
Parental Preferences and Shared Decision-Making for the Management of Febrile Young Infants
Parental Preferences and Shared Decision-Making for the Management of Febrile Young Infants
3:45
Nirsevimab Effectiveness Against Severe RSV Infection in the Primary Care Setting
Nirsevimab Effectiveness Against Severe RSV Infection in the Primary Care Setting

Currently loaded videos are 1 through 15 of 104 total videos.

First page loaded, no previous page available
Load Next Page